The results from an international trial, published by the Journal of Clinical Oncology, suggest that carboplatin-paclitaxel become the standard of care for anal cancer.
The results from an international trial, published by the Journal of Clinical Oncology, suggest that carboplatin-paclitaxel become the standard of care for anal cancer.